Login

Allergan plc

No Longer Reporting

The company has not filed an annual or quarterly report since its Q1 FY2020 10-Q, filed May 7, 2020. Its latest SEC filing is a 15-12B from May 21, 2020.

The sections below describe the company as of the FY2019 annual report.

What Did They Do?

Sold branded medicines and medical devices for medical aesthetics, eye care and other health needs to patients and physicians.

Who Were Their Customers?

Sold branded medicines and aesthetic products mainly through drug wholesalers, retailers and distributors to pharmacies, hospitals, clinics and health plans; some aesthetic products and devices were sold directly to physicians.

Did Revenues Turn Into Profits?

Not on paper. It lost $5.3B in FY2019, but brought in more cash than it spent: $6.9B of free cash flow.

Operating income, FY2019
−28% of revenue
▲ +29% (Loss) vs FY2018 (−$6.2B, −40%)
Net income, FY2019
−33% of revenue
▼ −3% (Loss) vs FY2018 (−$5.1B, −32%)
Free cash flow, FY2019
43% of revenue
▲ +27% vs FY2018 ($5.4B, 34%)

How Were They Changing?

Since the FY2019 annual report
Latest quarter: Q1 FY2020, the three months to Mar 31, 2020
Revenue
▲ 0%
vs $3.6B in Q1 FY2019
Net income
▲ Turned profitable
vs −$2.4B in Q1 FY2019
Botox share of revenue vs 24.1% in Q1 FY2019
  • May 8, 2020 AbbVie completed its acquisition of Allergan Allergan became a direct wholly owned subsidiary of AbbVie.
  • May 6, 2020 Allergan agreed to divest products under the FTC consent order The agreed sales covered brazikumab to AstraZeneca and Zenpep and Viokace to Nestle Health Science.

From generics to branded products The older report said Teva acquired Allergan’s global generics business; the latest described Allergan as focused on branded medicines, devices and related treatments.

Revenue over time
Botox Restasis Juvederm Collection Linzess/Constella Lumigan/Ganfort Bystolic/Byvalson Alphagan/Combigan Lo Loestrin Vraylar Eye Drops Alloderm Breast Implants Viibryd/Fetzima Coolsculpting Consumables Ozurdex Zenpep Carafate/Sulcrate Armour Thyroid Canasa/Salofalk Viberzi Asacol/Delzicol Coolsculpting Systems & Add On Applicators Skin Care Saphris Teflaro Namzaric Avycaz Rapaflo Savella Namenda Dalvance Aczone Liletta Kybella/Belkyra Other Products Revenues Tazorac Enablex Minastrin 24 Namenda XR SkinMedica Member] Lexapro Estrace Cream Namenda IR Other Latisse
$20B$10B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support